1. Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016;Mehta;Amyotroph Lateral Scler Frontotemporal Degener,2022
2. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015;Raymond;Amyotroph Lateral Scler Frontotemporal Degener,2019
3. Comparison of phenotypic characteristics and prognosis between black and white patients in a tertiary ALS clinic;Brand;Neurology,2021
4. Atlanta metropolitan area amyotrophic lateral sclerosis (ALS) surveillance: incidence and prevalence 2009–2011 and survival characteristics through 2015;Punjani;Amyotroph Lateral Scler Frontotemporal Degener,2020
5. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial;Lancet Neurol,2017